There is exciting news for patients with mesothelioma in the making. Two pharmaceutical companies have started a clinical phase II clinical trial to test the efficacy and activity of a new drug in mesothelioma. This new drug is named as PXD101. This is a small molecule histone deacetylase inhibitor.

National Cancer Institute is sponsoring the current clinical trial with CuraGen. Those who are having a diagnosis of mesothelioma, which is not removable by surgery and who have failed at least one line of chemotherapy are eligible for the clinical trial. The drug PXD101 is given by intravenous infusion once every three weeks.

The scientists are trying to determine if the drug PXD101 has any significant activity on mesothelioma in terms of clinical response. The study is also aimed at determining the safety of the drug and time to therapy failure. The study would also look for any survival advantage resulting from the use of the drug.

Scientists are planning to enroll a total of 37 patients at different sites across the United States.

Histone deacetylase inhibitors have the ability to down-regulate genes such as BCL-XL and VEGF and up-regulate cell-cycle regulating genes, including p21. Scientists say that they are excited to begin the trial and would evaluate PXD101 as a potential therapy for mesothelioma.

Sadly, there are no proven therapies available for patients who have progressed on the first line chemotherapy. PXD101 is expected to take this vacant position in the therapy algorithm.